Release
06.12.2017
Positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver, a risk factor for NASH
Download
Release
04.12.2017
Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practice
Download
Release
08.11.2017
VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claim
Download
Release
16.10.2017
LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans
Download
Release
29.09.2017
Consolidated results for the first half of 2017
Download
Release
20.09.2017
International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board
Download
Release
07.09.2017
Pascal SIRVENT appointed Director of Discovery and Preclinical Research
Download
Release
05.09.2017
VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®
Download
Release
09.06.2017
Results of Phase I/II clinical study on the active ingredient of Valedia®
Download